Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline

With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.

Business decline

Endo International PLC's decision July 6 to accede to the US FDA's request that it withdraw its long-acting opioid Opana ER (oxymorphone extended-release) is not a huge business setback on its own for the Irish specialty firm, but adds momentum to an overall revenue picture that is trending downward.

Following FDA's June 8 request that Endo voluntarily remove Opana ER – a reformulated version of the analgesic introduced in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.